Stock Scorecard

Stock Summary for Arcus Biosciences Inc (RCUS) - $14.15 as of 11/28/2023 8:55:48 PM EST

Total Score

10 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RCUS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RCUS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RCUS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for RCUS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for RCUS

Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period ( 2019-2032 ) | DelveInsight 11/21/2023 10:01:00 PM
It's Small Stocks' Time To Rally - Analysts Like These 11 Best 11/21/2023 1:00:00 PM
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity - Arcus Biosciences ( NYSE:RCUS ) , Gilead Sciences ( NASDAQ:GILD ) 11/7/2023 4:17:00 PM
Arcus Biosciences, Inc. ( RCUS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release 10/31/2023 2:01:00 PM
Stocks That Hit 52-Week Lows On Thursday - PRA Group ( NASDAQ:PRAA ) , Perimeter Solutions ( NYSE:PRM ) 10/5/2023 5:22:00 PM
Strength Seen in Adaptive Biotechnologies ( ADPT ) : Can Its 9.5% Jump Turn into More Strength? 9/27/2023 9:14:00 AM
Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis 9/6/2023 9:01:00 PM
Unlocking the Potential of TIGIT Antibodies: Market Insights and Clinical Progress in Immune Checkpoint Therapies 9/2/2023 12:30:00 AM
Biotech Stocks Rally After Roche's ( RHHBY ) Accidental Data Leak 8/24/2023 3:30:00 PM
Roche ( RHHBY ) Up on Upbeat Data From Combo Drug Cancer Study 8/24/2023 1:02:00 PM

Financial Details for RCUS

Company Overview
Ticker RCUS
Company Name Arcus Biosciences Inc
Country USA
Description Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2023
Next Earnings Date N/A

Stock Price History
Last Day Price 14.15
Last Day Price Updated 11/28/2023 8:55:48 PM EST
Last Day Volume 337,971
Average Daily Volume 760,175
52-Week High 36.13
52-Week Low 12.95
Last Price to 52 Week Low 9.27 %

Valuation Measures
Trailing PE N/A
Industry PE 56.90
Sector PE 61.34
5-Year Average PE 13.29
Free Cash Flow Ratio 1.33
Industry Free Cash Flow Ratio 10.31
Sector Free Cash Flow Ratio 30.12
Current Ratio Most Recent Quarter 4.41
Total Cash Per Share 10.67
Book Value Per Share Most Recent Quarter 6.95
Price to Book Ratio 3.15
Industry Price to Book Ratio 4.85
Sector Price to Book Ratio 21.70
Price to Sales Ratio Twelve Trailing Months 5.19
Industry Price to Sales Ratio Twelve Trailing Months 104.15
Sector Price to Sales Ratio Twelve Trailing Months 28.65

Share Statistics
Total Shares Outstanding 74,856,000
Market Capitalization 1,059,212,400
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Dividend King? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -603.77 %
Reported EPS 12 Trailing Months -4.00
Reported EPS Past Year -3.07
Reported EPS Prior Year -3.72
Net Income Twelve Trailing Months -293,456,000
Net Income Past Year -267,000,000
Net Income Prior Year 53,000,000
Quarterly Revenue Growth YOY -3.00 %
5-Year Revenue Growth 91.36 %

Balance Sheet
Total Cash Most Recent Quarter 799,000,000
Total Cash Past Year 1,009,000,000
Total Cash Prior Year 499,308,000
Net Cash Position Most Recent Quarter 799,000,000
Net Cash Position Past Year 1,009,000,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 657,000,000
Total Stockholder Equity Prior Year 842,000,000
Total Stockholder Equity Most Recent Quarter 520,000,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.76
MACD Signal -0.69
20-Day Bollinger Lower Band 13.18
20-Day Bollinger Middle Band 18.46
20-Day Bollinger Upper Band 23.73
Beta 0.76
RSI 41.96
50-Day SMA 19.89
200-Day SMA 25.87

System
Modified 11/28/2023 2:42:10 PM EST